Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Antimicrob Agents Chemother ; 57(12): 5808-10, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24002097

ABSTRACT

In this study, the efficacy of ceftaroline fosamil was compared with that of cefepime in an experimental rabbit meningitis model against two Gram-negative strains (Escherichia coli QK-9 and Klebsiella pneumoniae 1173687). The penetration of ceftaroline into inflamed and uninflamed meninges was also investigated. Both regimens were bactericidal, but ceftaroline fosamil was significantly superior to cefepime against K. pneumoniae and E. coli in this experimental rabbit meningitis model (P < 0.0007 against K. pneumoniae and P < 0.0016 against E. coli). The penetration of ceftaroline was approximately 15% into inflamed meninges and approximately 3% into uninflamed meninges.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cephalosporins/pharmacology , Klebsiella Infections/drug therapy , Meningitis, Escherichia coli/drug therapy , Animals , Anti-Bacterial Agents/cerebrospinal fluid , Anti-Bacterial Agents/pharmacokinetics , Cefepime , Cephalosporins/cerebrospinal fluid , Cephalosporins/pharmacokinetics , Disease Models, Animal , Escherichia coli/drug effects , Escherichia coli/physiology , Klebsiella Infections/cerebrospinal fluid , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/physiology , Meninges/drug effects , Meninges/metabolism , Meninges/microbiology , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/microbiology , Permeability , Rabbits , Treatment Outcome , Ceftaroline
2.
Niger Postgrad Med J ; 20(1): 9-13, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23661203

ABSTRACT

AIMS AND OBJECTIVES: To determine the common aetiolog of acute bacterial meningitis in children and their antibiotic susceptibility pattern. MATERIALS AND METHODS: A retrospective study with a review of cerebrospinal fluid culture reports of paediatric patients aged 0-15 years, suspected of acute meningitis in the Medical Microbiology Department of Aminu Kano Teaching Hospital, Kano, Nigeria from October 2006 to October 2009 from October 2006 to October 2009. RESULTS: A positive culture bacterial isolation rate of 3.3% (n=50/1500) with prevalence of Streptococcus pneumoniae (24%), Neisseria meningitidis (22%), Escherichia coli (16%), Haemophilus influenzae (14%), Group B streptococci (8%) and Enterococci (8%) which were susceptible to ceftriaxone (96%), cefotaxime (95%) and ciprofloxacin (93%) across the bacterial isolates. Neonates were 55% (n=6.8/12.4) most at risk. CONCLUSION: Neonates are the most at risk of acute bacterial meningitis. In the absence of antibiotic susceptibility report, ceftriaxone should be considered as a first choice reliable antibiotic for empirical treatment of meningitis in children, in this environment.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Bacterial/microbiology , Adolescent , Cefotaxime/therapeutic use , Ceftriaxone/therapeutic use , Cerebrospinal Fluid/microbiology , Child , Child, Preschool , Ciprofloxacin/therapeutic use , Enterococcus/isolation & purification , Escherichia coli/isolation & purification , Haemophilus influenzae/isolation & purification , Humans , Infant , Infant, Newborn , Meningitis, Bacterial/drug therapy , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Haemophilus/cerebrospinal fluid , Meningitis, Haemophilus/microbiology , Meningitis, Meningococcal/cerebrospinal fluid , Meningitis, Pneumococcal/cerebrospinal fluid , Microbial Sensitivity Tests , Nigeria , Retrospective Studies , Streptococcus agalactiae/isolation & purification , Tertiary Care Centers
3.
J Microbiol Immunol Infect ; 45(6): 442-7, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22571998

ABSTRACT

BACKGROUND: Bacterial meningitis has long been a severe infectious disease in neonates, as well as a leading cause of adverse outcomes. We designed this study to know the factors for poor prognosis in neonatal bacterial meningitis. METHODS: We enrolled children aged less than 1 month who were admitted to Mackay Memorial Hospital from 1984 to 2008 and had culture-proven bacterial meningitis. The laboratory data and children's clinical features were recorded. The patients' outcomes were divided into four groups: death, having sequelae, complete recovery, and loss to follow-up. Patients with the outcomes of death and having sequelae were regarded as having a poor prognosis. Those who were lost to follow-up were excluded from the analysis of outcome. Multivariate analyses were performed to find the risk factors for poor prognosis. RESULTS: One hundred fifty-six neonates fulfilled the inclusion criteria. Among these, 96 were boys (61.5%) and 102 (65.4%) had concomitant bacteremia. Group B streptococci (39.1%) and Escherichia coli (20.1%) were the two leading pathogens. Excluding those who were lost to follow-up (4.5%), 22 of 149 patients (14.8%) died, 36 (24.2%) had sequelae, and 91 (61.1%) recovered completely. Cerebrospinal fluid (CSF) protein more than 500 mg/dL at admission {odds ratio (OR): 171.18 [95% confidence interval (CI): 25.6-1000]}, predisposition to congenital heart disease [OR: 48.96 (95% CI: 6.06-395.64)], hearing impairment found during hospitalization [OR: 23.40 (95% CI: 3.62-151.25)], and seizure at admission or during hospitalization [OR: 10.10 (95% CI: 2.11-48.32)] were the factors predicting poor prognosis. CONCLUSION: In this 25-year study of newborns with bacterial meningitis, approximately one-seventh of the patients died, while two-fifths had sequelae. Nearly two-thirds of these had concomitant bacteremia. Group B streptococci and E. coli remained the two leading pathogens throughout the study period. Several factors for poor prognosis in newborns with culture-proven bacterial meningitis were found: high CSF protein concentration, congenital heart disease, hearing impairment, and seizure.


Subject(s)
Escherichia coli/isolation & purification , Meningitis, Bacterial/diagnosis , Meningitis, Escherichia coli/diagnosis , Streptococcus agalactiae/isolation & purification , Child, Preschool , Female , Hospitalization , Humans , Infant , Infant, Newborn , Male , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Bacterial/complications , Meningitis, Bacterial/microbiology , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/complications , Meningitis, Escherichia coli/microbiology , Prognosis , Risk Factors , Taiwan
4.
J Neurol Sci ; 280(1-2): 59-61, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19237165

ABSTRACT

Neurofilament (NF) is one of the major cytoskeleton proteins of neurons. We investigated the concentrations of the heavy subunit of NF (NF-H) in cerebrospinal fluid (CSF) as biomarkers of neuronal injury in bacterial meningitis. Concentrations of NF-H in CSF of 26 children with bacterial meningitis and in 16 control subjects were measured by ELISA. The CSF NF-H levels were elevated in 22 of the 26 children (85%) with bacterial meningitis. The peak CSF NF-H level occurred at a median period of 10.5 days after onset of illness (range, 1 to 35 days). The peak CSF NF-H levels of the patients with neurological sequelae (n=4) were significantly higher than those without sequelae (n=22) (7.06 vs. 2.46 ng/mL as median, p=0.048). There was no significant difference in CSF NF-H levels between patients with and without severe neurological sequelae up to day 14 of illness, but the CSF NF-H levels in patients with sequelae were significantly higher than in those without sequelae after day 14 of illness (2.04 vs. 1.19 ng/mL as median, p=0.024). We suggest that neuronal injury occurs in bacterial meningitis regardless of the presence or absence of neurological sequelae.


Subject(s)
Meningitis, Bacterial/cerebrospinal fluid , Neurofilament Proteins/cerebrospinal fluid , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Hearing Loss, Sensorineural/cerebrospinal fluid , Hearing Loss, Sensorineural/complications , Humans , Infant , Infant, Newborn , Intellectual Disability/cerebrospinal fluid , Intellectual Disability/complications , Male , Meningitis, Bacterial/complications , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/complications , Meningitis, Haemophilus/cerebrospinal fluid , Meningitis, Haemophilus/complications , Meningitis, Pneumococcal/cerebrospinal fluid , Meningitis, Pneumococcal/complications , Methicillin-Resistant Staphylococcus aureus , Paresis/cerebrospinal fluid , Paresis/complications , Time Factors
5.
Pediatr Res ; 62(6): 680-3, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17957150

ABSTRACT

Despite effective antibiotic treatment, neuronal injury is frequent among children and adults with bacterial meningitis resulting in a high rate of death and neurologic sequelae. The hematopoietic cytokine erythropoietin (EPO) provides neuroprotection in models of acute and chronic neurologic diseases. We studied whether recombinant EPO (rEPO) reduces neuronal damage in a rabbit model of Escherichia coli meningitis. Inflammation within the central nervous system (CNS) was monitored by measurement of bacterial load, pleocytosis, protein, and lactate in the cerebrospinal fluid (CSF). Neuronal damage was measured by quantification of the density of apoptotic neurons in the hippocampal dentate gyrus and the concentration of the global neuronal destruction marker neuron-specific enolase (NSE) in CSF. To increase clinical relevance, rEPO was applied as adjunctive therapy from the beginning of antibiotic therapy 12 h after infection. EPO treatment applied as an intravenous injection at a dose of 1000 IU/kg body weight resulted in plasma concentrations of 6993 +/- 1406 mIU/mL, CSF concentrations of 1291 +/- 568 mIU/mL, and a CSF-to-plasma ratio of 0.18 +/- 0.07 (mean +/- SD) 6 h after injection. Under these treatment conditions, no anti-inflammatory or neuroprotective effect of EPO was observed. "


Subject(s)
Anti-Inflammatory Agents/pharmacology , Apoptosis/drug effects , Dentate Gyrus/drug effects , Erythropoietin/pharmacology , Meningitis, Escherichia coli/drug therapy , Nervous System Diseases/prevention & control , Neurons/drug effects , Neuroprotective Agents/pharmacology , Animals , Anti-Bacterial Agents/pharmacology , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/blood , Anti-Inflammatory Agents/cerebrospinal fluid , Dentate Gyrus/pathology , Disease Models, Animal , Drug Therapy, Combination , Erythropoietin/administration & dosage , Erythropoietin/blood , Erythropoietin/cerebrospinal fluid , Injections, Intravenous , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/complications , Meningitis, Escherichia coli/pathology , Nervous System Diseases/cerebrospinal fluid , Nervous System Diseases/microbiology , Nervous System Diseases/pathology , Neurons/enzymology , Neurons/pathology , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/blood , Neuroprotective Agents/cerebrospinal fluid , Phosphopyruvate Hydratase/cerebrospinal fluid , Rabbits , Recombinant Proteins , Severity of Illness Index , Time Factors
6.
Infect Immun ; 74(4): 2196-206, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16552050

ABSTRACT

Escherichia coli is a major cause of enteric/diarrheal diseases, urinary tract infections, and sepsis. E. coli K1 is the leading gram-negative organism causing neonatal meningitis, but the microbial basis of E. coli K1 meningitis is incompletely understood. Here we employed comparative genomic hybridization to investigate 11 strains of E. coli K1 isolated from the cerebrospinal fluid (CSF) of patients with meningitis. These 11 strains cover the majority of common O serotypes in E. coli K1 isolates from CSF. Our data demonstrated that these 11 strains of E. coli K1 can be categorized into two groups based on their profile for putative virulence factors, lipoproteins, proteases, and outer membrane proteins. Of interest, we showed that some open reading frames (ORFs) encoding the type III secretion system apparatus were found in group 2 strains but not in group 1 strains, while ORFs encoding the general secretory pathway are predominant in group 1 strains. These findings suggest that E. coli K1 strains isolated from CSF can be divided into two groups and these two groups of E. coli K1 may utilize different mechanisms to induce meningitis.


Subject(s)
Escherichia coli/genetics , Genome, Bacterial , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/microbiology , Bacterial Outer Membrane Proteins/genetics , Escherichia coli/pathogenicity , Escherichia coli Proteins/genetics , Humans , Lipoproteins/genetics , Peptide Hydrolases/genetics , Phylogeny , Virulence Factors/genetics
7.
Ann Trop Med Parasitol ; 98(1): 65-70, 2004 Jan.
Article in English | MEDLINE | ID: mdl-15000733

ABSTRACT

Bacterial meningitis remains an important cause of morbidity and mortality in Vietnam. Diagnosis is hampered by the ready availability of antibiotics in the community, leading to late presentation, masked clinical signs, and poor organism detection during the microscopical examination and culture of cerebrospinal fluid (CSF). In order to improve organism detection at the Hospital for Tropical Diseases in Ho Chi Minh City, a diagnostic PCR-based protocol was developed. This protocol was followed in the investigation of CSF samples from 36 patients with clinical signs of bacterial meningitis. Each sample was first tested in a semi-nested PCR using primers for the 16sRNA gene common to all bacteria. The products of this reaction were then amplified using a 16sru8 primer and primers specific for Neisseria meningitidis, Haemophilus influenzae or Streptococcus spp. The samples found positive for Streptococcus were further investigated in a nested PCR using primers specific for the pneumolysin gene of S. pneumoniae. The sensitivity of detection was increased from 36% with culture to 44% with PCR. Although the sample size was small, the results indicate that PCR would be a feasible and useful adjunct in the diagnosis of bacterial meningitis, particularly in areas where community antibiotic use is common.


Subject(s)
Meningitis, Bacterial/diagnosis , Polymerase Chain Reaction/methods , Antigens, Bacterial/analysis , Humans , Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/diagnosis , Meningitis, Haemophilus/cerebrospinal fluid , Meningitis, Haemophilus/diagnosis , Meningitis, Meningococcal/cerebrospinal fluid , Meningitis, Meningococcal/diagnosis , Meningitis, Pneumococcal/cerebrospinal fluid , Meningitis, Pneumococcal/diagnosis , Sensitivity and Specificity , Vietnam
8.
Urologe A ; 42(12): 1611-5, 2003 Dec.
Article in German | MEDLINE | ID: mdl-14668990

ABSTRACT

Acute meningitis caused by Escherichia coli is a rare disease in adulthood. Medical procedures, e.g. surgical interventions, have been described as a cause. Infection by blood transmission of fecal E. coli is also known. We report a case of acute meningitis after transrectal prostate biopsy. E. coli could be identified both in the cerebrospinal fluid and in the blood culture. A broad initial antibiotic therapy was administered. After cultural isolation of E. coli the therapy was switched to cefotaxime. The initially comatose patient recovered swiftly.


Subject(s)
Biopsy, Needle/adverse effects , Meningitis, Escherichia coli/drug therapy , Meningitis, Escherichia coli/etiology , Prostate/pathology , Rectum/microbiology , Acute Disease , Cefotaxime/therapeutic use , Escherichia coli/isolation & purification , Humans , Male , Meningitis, Escherichia coli/blood , Meningitis, Escherichia coli/cerebrospinal fluid , Middle Aged , Rectum/pathology
9.
Antimicrob Agents Chemother ; 45(11): 3092-7, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11600361

ABSTRACT

Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Deltalog(10) CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C(max)/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF.


Subject(s)
Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/therapeutic use , Aza Compounds , Fluoroquinolones , Meningitis, Escherichia coli/drug therapy , Quinolines , Animals , Anti-Infective Agents/cerebrospinal fluid , Area Under Curve , Ceftriaxone/therapeutic use , Cephalosporins/therapeutic use , Escherichia coli/drug effects , Male , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/microbiology , Meropenem , Microbial Sensitivity Tests , Moxifloxacin , Rabbits , Thienamycins/therapeutic use
10.
Clin Infect Dis ; 33(9): e109-11, 2001 Nov 01.
Article in English | MEDLINE | ID: mdl-11577376

ABSTRACT

We have assessed levofloxacin penetration in cerebrospinal fluid (CSF) and the liquor-to-plasma ratio (C(L)/C(P)) at 2 hours after dosing in 5 patients with spontaneous acute bacterial meningitis. CSF levofloxacin concentration at 2 hours after dosing was 1.99+/-0.67 microg/mL, and the C(L)/C(P) at 2 hours after dosing was 0.34+/-0.09.


Subject(s)
Anti-Infective Agents/cerebrospinal fluid , Levofloxacin , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Meningococcal/cerebrospinal fluid , Meningitis, Pneumococcal/cerebrospinal fluid , Ofloxacin/cerebrospinal fluid , Acute Disease , Adult , Aged , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/therapeutic use , Female , Humans , Male , Meningitis, Escherichia coli/drug therapy , Meningitis, Meningococcal/drug therapy , Meningitis, Pneumococcal/drug therapy , Middle Aged , Ofloxacin/pharmacokinetics , Ofloxacin/therapeutic use
11.
Biol Neonate ; 80(1): 53-9, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11474150

ABSTRACT

We evaluated the anti-inflammatory and neuroprotective effects of the selective neuronal nitric oxide synthase inhibitor 7-nitroindazole and aminoguanidine, which predominantly inhibits inducible nitric oxide synthase, during the early phase of experimental bacterial meningitis in the newborn piglet. Meningitis was induced by intracisternal injection of 10(8) colony-forming units of Escherichia coli in 100 microl of saline. 7-Nitroindazole significantly attenuated the meningitis-induced acute inflammatory responses such as increased intracranial pressure, decreased cerebrospinal fluid (CSF) glucose concentration, and CSF leukocytosis at 2 h. However, meningitis-induced CSF leukocytosis at 4 h and increased CSF lactate and tumor necrosis factor alpha levels were not significantly attenuated. Reduced cerebral cortical cell membrane Na(+),K(+)-ATPase activity and increased lipid peroxidation products, indicative of meningitis-induced brain cell membrane dysfunction, were also significantly improved with 7-nitroindazole treatment. In contrast, although aminoguanidine significantly attenuated the increase in the CSF tumor necrosis factor alpha level, it failed to attenuate the acute inflammation and the ensuing brain injury in bacterial meningitis. In summary, 7-nitroindazole, but not aminoguanidine, significantly attenuated the acute inflammatory responses and brain injury during the early phase of neonatal bacterial meningitis.


Subject(s)
Animals, Newborn , Brain Diseases/prevention & control , Guanidines/therapeutic use , Indazoles/therapeutic use , Inflammation/prevention & control , Meningitis, Escherichia coli/complications , Animals , Blood Glucose/analysis , Brain Diseases/etiology , Cerebral Cortex/chemistry , Cerebral Cortex/enzymology , Cerebrospinal Fluid/cytology , Disease Models, Animal , Enzyme Inhibitors/therapeutic use , Glucose/analysis , Glucose/cerebrospinal fluid , Lactic Acid/analysis , Lactic Acid/blood , Lactic Acid/cerebrospinal fluid , Leukocytosis , Lipid Peroxidation , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Swine , Tumor Necrosis Factor-alpha/cerebrospinal fluid
12.
Neurol Res ; 23(4): 410-6, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11428523

ABSTRACT

The aim of the present study was to evaluate the anti-inflammatory and neuroprotective effects of a poly (ADP-ribose) synthetase inhibitor 3-aminobenzamide during the early phase of experimental bacterial meningitis in the newborn piglet. Meningitis was induced by intracisternal injection of 10(8) colony forming units of Escherichia coli in 100 microl of saline. 3-Aminobenzamide, given 30 mg kg(-1) as a bolus i.v. injection 30 min before induction of meningitis, significantly attenuated the meningitis-induced acute inflammatory responses such as increased cerebrospinal fluid (CSF) lactate concentration, CSF leukocytosis and increased CSF tumor necrosis factor-alpha level. However, meningitis-induced increase in intracranial pressure and decrease in CSF glucose level were not significantly improved. Increased cerebral cortical cell membrane lipid peroxidation products (conjugated dienes) and decreased brain ATP/phosphocreatine levels observed in the meningitis group were also significantly improved with 3-aminobenzamide treatment. However, the improvement of reduced Na+, K+-ATPase activity did not reach a statistical significance (p = 0.06). In summary, 3-aminobenzamide significantly attenuated the acute inflammatory responses and the ensuing brain injury during the early phase of neonatal bacterial meningitis. These findings suggest that poly (ADP-ribose) synthetase inhibitors such as 3-aminobenzamide might be a promising novel anti-inflammatory and neuroprotective adjuvant therapy in neonatal bacterial meningitis.


Subject(s)
Benzamides/pharmacology , Brain/pathology , Encephalitis/pathology , Enzyme Inhibitors/pharmacology , Meningitis, Escherichia coli/pathology , Poly Adenosine Diphosphate Ribose/antagonists & inhibitors , Poly(ADP-ribose) Polymerase Inhibitors , Acute Disease , Animals , Animals, Newborn , Brain/metabolism , Cerebral Cortex/metabolism , Colony Count, Microbial , Escherichia coli/isolation & purification , Glucose/metabolism , Lactic Acid/metabolism , Leukocyte Count , Meningitis, Escherichia coli/blood , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/microbiology , Swine , Tumor Necrosis Factor-alpha/metabolism
13.
Int J Clin Lab Res ; 30(3): 127-31, 2000.
Article in English | MEDLINE | ID: mdl-11196070

ABSTRACT

Nitric oxide is very likely to play a role in physiopathological mechanisms of bacterial meningitis. As shown by in vitro studies, nitric oxide is toxic to endothelial cells, as well as to neurones, and thus may be responsible for neurological sequelae in bacterial meningitis. Increased level of nitric oxide can also inhibit mitochondrial respiration, enhancing anaerobic glycolysis. Twenty-seven children with documented bacterial meningitis, 73 with viral (mumps and enteroviral) meningitis, and 51 controls were studied. All children with bacterial meningitis were given cefotaxime (200 mg/kg per day). Glucose and protein concentrations and cerebrospinal fluid cell counts were determined routinely, as well as nitrite and nitrate levels. The levels of nitrite and nitrate in cerebrospinal fluid on admission were higher in patients with bacterial meningitis than in controls or in children with viral meningitis. In 10 patients, dexamethasone therapy (0.4 mg/kg every 12 h for 2 days) was started about 10 min before the first antibiotic dose. A significantly lower nitrite concentration was observed after 24-48 h of treatment compared with non-steroid-treated patients. Significant positive correlations between the nitrite and granulocyte counts and the protein concentration in cerebrospinal fluid were found in all patients with meningitis. Increased nitric oxide production in cerebrospinal fluid during the acute phase of bacterial meningitis may result from the inflammatory process and tissue injury. Dexamethasone administered before the first parenteral antibiotic dose seems to reduce nitric oxide production in the cerebrospinal fluid during bacterial meningitis.


Subject(s)
Meningitis, Bacterial/cerebrospinal fluid , Meningitis, Viral/cerebrospinal fluid , Nitric Oxide/cerebrospinal fluid , Adolescent , Anti-Inflammatory Agents/therapeutic use , Child , Child, Preschool , Dexamethasone/therapeutic use , Echovirus Infections/cerebrospinal fluid , Humans , Infant , Meningitis, Bacterial/drug therapy , Meningitis, Escherichia coli/cerebrospinal fluid , Meningitis, Escherichia coli/drug therapy , Meningitis, Meningococcal/cerebrospinal fluid , Meningitis, Meningococcal/drug therapy , Meningitis, Pneumococcal/cerebrospinal fluid , Meningitis, Pneumococcal/drug therapy , Nitrates/cerebrospinal fluid , Nitric Oxide/metabolism , Nitrites/cerebrospinal fluid , Rubulavirus Infections/cerebrospinal fluid
SELECTION OF CITATIONS
SEARCH DETAIL
...